| Literature DB >> 26614611 |
Qixia Wang1, Fan Yang1, Qi Miao1, Edward L Krawitt2, M Eric Gershwin3, Xiong Ma4.
Abstract
Autoimmune hepatitis (AIH) fulfills the generally accepted contemporary criteria of an autoimmune liver disease: the presence of autoantibodies and autoreactive T cells, a female gender bias, association with other autoimmune diseases, response to immunosuppressive therapy and strong associations with the major histocompatibility complex HLA loci. It occurs worldwide in both children and adults and is marked by both etiopathogenic and clinical heterogeneity, differing from the other putative autoimmune liver diseases, primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), albeit occasionally presenting with overlapping features of PBC or PSC. Although diagnostic criteria have been established and validated, there are still major issues to be clarified due to its variability, such as autoantibody-negative AIH, drug-induced AIH, AIH sharing features with PBC or PSC, and post-transplant de novo AIH. In view of the diverse presentations and courses, including classical chronic onset, acute and acute severe onset, cirrhosis and decompensated cirrhosis, individualized management of patients is indicated. Each patient should receive a personalized analysis of the benefits and side effect risks of drugs. Herein we describe a comprehensive review of the clinical phenotypes of AIH underscoring its clinical heterogeneity.Entities:
Keywords: Acute hepatitis; Autoantibodies; Autoimmune hepatitis; Chronic hepatitis; Drug-induced liver injury; Jaundice; Liver failure; Liver transplantation
Mesh:
Substances:
Year: 2015 PMID: 26614611 DOI: 10.1016/j.jaut.2015.10.006
Source DB: PubMed Journal: J Autoimmun ISSN: 0896-8411 Impact factor: 7.094